|
FDU-PB-22
FDU-PB-22 is a derivative of JWH-018 that is presumed to be a potent agonist of the CB1 receptor, and has been sold online as a designer drug. Pharmacology FDU-PB-22 acts as a full agonist with a binding affinity of 1.19nM at CB1 and 2.43nM at CB2 cannabinoid receptors. Legal status FDU-PB-22 is a controlled substance in Germany and is banned in Japan and Sweden. See also * 5F-PB-22 * AM-2201 * BB-22 * FUB-JWH-018 * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * FUB-144 * FUB-APINACA * FUB-PB-22 * MDMB-FUBICA * MDMB-FUBINACA * PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ... References Designer drugs Fluoroarenes Naphthoylindoles Indolecarboxylates {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-JWH-018
FUB-JWH-018 (also known as FUB-018) is a naphthoylindole-based synthetic cannabinoid, representing a molecular hybrid of JWH-018 and AB-FUBICA or ADB-FUBICA. Legal status In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as FUB-JWH-018 are Schedule I Controlled Substances. As of October 2015 FUB-JWH-018 is a controlled substance in China. See also * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * CHM-018 * FUB-144 * FUB-APINACA * FDU-PB-22 * FUB-PB-22 * MDMB-FUBICA * MDMB-FUBINACA MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with ''K''i values of 1.14 nM at CB1 and 0.1228 nM at CB2 and EC50 values of ... References Designer drugs Naphthoylindoles Fluoroarenes {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-PB-22
FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. Pharmacology FUB-PB-22 acts as a full agonist with a binding affinity of 0.386nM at CB1 and 0.478nM at CB2 cannabinoid receptors. Legal status FUB-PB-22 is an Anlage II controlled substance in Germany. It was scheduled in Japan in July 2014. As of October 2015 FUB-PB-22 is a controlled substance in China. It is also banned in Sweden. See also * 2F-QMPSB * 5F-PB-22 * AM-2201 * BB-22 * FUB-JWH-018 * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * FDU-PB-22 * FUB-144 * FUB-APINACA * MDMB-FUBICA * MDMB-FUBINACA * PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ... References Cannabinoids Designer drugs Fluoroar ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Drugs Controlled By The German Betäubungsmittelgesetz
Drugs controlled by the German ''Betäubungsmittelgesetz'' (BtMG). Trade and drug possession, possession of these substances without licence or prescription is considered illegal; prescription is illegal for drugs on ''Anlage I'' and II and drugs on ''Anlage III'' require a special prescription form. ''Anlage I'' ''Anlage I'' controlled substances are tradability, non-tradable. Those substances are available only by special permission of the authorities, which is granted only for scientific or other public interest purposes. As well as ester, ether, Stereoisomerism, stereoisomers and salts of the substances listed in ''Anlage I''. '' Anlage II'' ''Anlage II'' controlled substances are tradability, tradable, given special permission of the authorities, however not medical prescription , prescriptible. Narcotics on ''Anlage II'' are usually needed for the production of other narcotics on ''Anlage III''. As well as ester, ether and salts of the substances listed in ''Anlage II'' ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-FUBINACA
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported. Its use has been linked to hospitalizations and deaths. Legality It was designated as a Schedule I controlled substance in the United States in January 2014. It is an Anlage II controlled substance in Germany as of November 2014. Since October 2015 AB-FUBINACA is a controlled substance in China . In December 2019, the UNODC announced scheduling recommendations placing AB-FUBINACA as a controlled research chemical into Schedule II. 101789 Mass overdoses due to adulterated K2 On August 15th, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects, and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human trials, the use of some of these drugs may result i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PB-22
PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represents a structurally unique synthetic cannabinoid chemotype, since it contains an ester linker at the indole 3-position, rather than the precedented ketone of JWH-018 and its structural analog, analogs, or the amide of APICA (synthetic cannabinoid drug), APICA and its analogs. PB-22 has an EC50, EC50 of 5.1 nM for human CB1 receptors, and 37 nM for human CB2 receptors. PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity. The magnitude and duration of hypothermia induced in rats by PB-22 was notably greater than JWH-018, AM-2201, UR-144, XLR-11, APICA (synthetic cannabinoid drug), APICA, or STS-135 (drug), STS-135, with a reduction of body temperature still obse ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-FUBINACA
MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with ''K''i values of 1.14 nM at CB1 and 0.1228 nM at CB2 and EC50 values of 0.2668 nM at CB1 and 0.1411 nM at CB2, and has been sold online as a designer drug. Its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB1 receptor (''K''i = 0.14 nM, EC50 = 2.42 nM). The structure of MDMB-FUBINACA contains the amino aci3-methylvalineor tert-leucine methyl ester. Side effects There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold by 2015. Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and govern ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-FUBICA
MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It was first detected by the EMCDDA in Sweden in February 2015. It is often sold in e-liquid form for use in an electronic cigarette. Side effects MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015. Legality MDMB-FUBICA is banned in Sweden. See also * 5F-AB-PINACA * 5F-ADB * 5F-AMB * 5F-APINACA * AB-FUBINACA * AB-CHFUPYCA * AB-CHMINACA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * AMB-FUBINACA * APINACA * APP-FUBINACA * FUB-APINACA * MDMB-CHMICA * MDMB-CHMINACA * PX-3 PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 200 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-APINACA
FUB-APINACA (also known as AFUBINACA and FUB-AKB48) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is an analog of APINACA and 5F-APINACA where the pentyl chain has been replaced with fluorobenzyl. Pharmacology FUB-APINACA acts as a full agonist with a binding affinity of 1.06 nM at CB1 and 0.174 nM at CB2 cannabinoid receptors. Legal status In the United States, FUB-APINACA was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance nationwide on April 7, 2022. Previously, it was illegal only in Alabama (listed as FUB-AKB48). Sweden's public health agency suggested classifying FUB-APINACA as a hazardous substance on November 10, 2014. See also * 5F-ADB * 5F-AMB * AB-FUBINACA * AB-CHFUPYCA * AB-PINACA * ADAMANTYL-THPINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADBICA * APP-FUBINACA * FAB-144 * MDMB-CH ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-144
FUB-144 (also known as FUB-UR-144) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is an analogue of UR-144 and XLR-11 where the pentyl chain has been replaced with fluorobenzyl. Legal status In the United States, FUB-144 was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance on April 7, 2022. Sweden's public health agency suggested classifying FUB-144 as hazardous substance on March 24, 2015. See also * A-834,735 * AB-005 AB-005 or -[(1-methylpiperidin-2-yl)methyl1''H''-indol-3-yl">1-methylpiperidin-2-yl)methyl.html" ;"title="-[(1-methylpiperidin-2-yl)methyl">-[(1-methylpiperidin-2-yl)methyl1''H''-indol-3-yl2,2,3,3-tetramethylcyclopropyl)-methanone is a designer ... * FAB-144 * JWH-018 * STS-135 (drug), STS-135 References {{Cannabinoids Cannabinoids Designer drugs Fluoroarenes Indoles [ ategory:Tetramethylcyclopr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AMB-FUBINACA
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with ''K''i values of 10.04 nM at CB1 and 0.786 nM at CB2 and EC50 values of 0.5433 nM at CB1 and 0.1278 nM at CB2, and has been sold online as a designer drug. It was originally developed by Pfizer which described the compound in a patent in 2009, but was later abandoned and never tested on humans. AMB-FUBINACA was the most common synthetic cannabinoid identified in drug seizures by the Drug Enforcement Administration in 2017 and the first half of 2018. Mass casualties On July 12, 2016, the New York City Emergency Medical Services responded to a "mass casualty event" in Brooklyn, New York, where 33 people ranging in age from 25 to 59 years old were adversely affected by the drug. 18 were hospitalized. All of the victims were described by-standers as “zombielike” and the cause was attributed to u ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |